Health Canada has recently approved an expanded use for enzalutamide (Xtandi) so that it can now be prescribed to treat men with non-metastatic castration-resistant prostate cancer (nmCRPC).
It was announced today that the Phase 3 ARCHES trial which evaluated XTANDI (enzalutamide) along with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone.
Why are Zytiga and Xtandi added to ADT and not substituted for ADT? Do I really need to continue ADT when I use Xtandi or Zytiga?
You have become castrate resistant and already have taken Provenge. Now, what treatment should be next? Currently, the two best options are either Zytiga (abiraterone) or Xtandi (enzalutamide). Which should come first?
Earlier studies of men with metastatic prostate cancer who took enzalutamide (Xtandi) indicated that there might be an increase in the risk having a seizure. Is this risk real? The UPWARD Study
One of the most puzzling questions faced by men with advanced prostate cancer has to do with deciding which drug to take first, Zytiga (abiraterone) or Xtandi (enzalutamide)?